Michael MacManus

Peri-transplant radiotherapy in refractory or relapsed Hodgkin lymphoma patients undergoing autologous stem cell transplant: long term results of a retrospective study of the Fondazione Italiana Linfomi (FIL).

Mario Levis, Belinda A Campbell, Fabio Matrone, Lavinia Grapulin, Anna Di Russo, Michela Buglione, Ilenia Iamundo De Cumis, Gabriele Simontacchi, Patrizia Ciammella, Alessandro Magli, Giuliana Pascale, Sofia Meregalli, Michael MacManus, Giuseppe Fanetti, Francesca De Felice, Gabriella Furfaro, Giovannino Ciccone, Umberto Ricardi

Journal article  |  2023  |  Int J Radiat Oncol Biol Phys

PURPOSE: In this multicenter collaboration, we report real-world data in the largest published series of long-term outcomes for pa..

An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer.

Richard J Lobb, Kekoolani S Visan, Li-Ying Wu, Emma L Norris, Marcus L Hastie, Sarah Everitt, Ian A Yang, Rayleen V Bowman, Shankar Siva, Jill E Larsen, Jeffrey J Gorman, Michael MacManus, Antoine Leimgruber, Kwun M Fong, Andreas Möller

Journal article  |  2023  |  Commun Biol

Despite significant therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide1. Non-small cell..

Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases

Shankar Siva, Gavin Jones, Mathias Bressel, Mark Shaw, Sarat Chander, Julie Chu, Nikki Plumridge, Keelan Byrne, Gargi Kothari, Nicholas Hardcastle, Mathieu Gaudreault, Tomas Kron, Greg Wheeler, Michael MacManus, Gerard G Hanna, David L Ball, Steven David

Journal article  |  2022  |  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PURPOSE: Medical operability is prognostic for survival after SABR in primary malignancies. This study investigated the prognostic..

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, Jenny Trinh, Thomas John, Lisa Devereux, Paul S Donnelly, Rod Hicks, Andrew M Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G Hanna, Jason Callahan, Kate Burbury, Michael MacManus

Journal article  |  2022  |  BMJ Open

BACKGROUND: ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if 89Zr-durvalumab PET/CT can be used t..

P1.10-02 ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation

M MacManus, S Rudd, P Roselt, C Wichmann, J Callahan, T John, A Scott, P Donnelly, G Hanna, F Hegi-Johnson

Journal article  |  2022  |  Journal of Thoracic Oncology

MA09.05 Increased PD-L1 Tracer Uptake in Recently-irradiated Lesions in NSCLC: Preliminary Results of a Phase 0 Trial (ImmunoPET) of a Novel PET Tracer

F Hegi-Johnson, T Akhurst, S Rudd, P Donnelly, A Scott, J Callahan, P Roselt, T John, S Sithara, C Wichmann, G Hanna, M MacManus

Journal article  |  2022  |  Journal of Thoracic Oncology

P2.03-01 Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT

F Hegi-Johnson, S Rudd, J Callahan, C Wichmann, T Akhurst, P Roselt, T John, P Donnelly, A Scott, G Hanna, M MacManus

Journal article  |  2022  |  Journal of Thoracic Oncology

Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study

Sweet Ping Ng, Carlos E Cardenas, Houda Bahig, Baher Elgohari, Jihong Wang, Jason M Johnson, Amy C Moreno, Shalin J Shah, Adam S Garden, Jack Phan, G Brandon Gunn, Steven J Frank, Yao Ding, Lumine Na, Ying Yuan, Diana Urbauer, Abdallah SR Mohamed, David Rosenthal, William H Morrison, Michael P MacManus, et al.

Journal article  |  2022  |  CURRENT ONCOLOGY

Background: The PREDICT-HN study aimed to systematically assess the kinetics of imaging MR biomarkers during head and neck radioth..

EP14.05-016 Patterns of Care for Small Cell Lung Cancer in Victoria Australia. A Prospective Population-Based Observational Study

J Huang, W Faisal, M Brand, S Smith, M Alexander, M Conron, M Duffy, L Briggs, J Lesage, J Philip, T John, E Samuel, M MacManus, P Mitchell, I Olesen, P Parente, C Underhill, J Zalcberg, S Harden, R Stirling

Journal article  |  2022  |  Journal of Thoracic Oncology

Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: An application of the TARGET-TP score.

Kate Burbury, Marliese Alexander, Samuel J Harris, Craig Underhill, Javier Torres, Sharad Sharma, Nora Lee, Hui-Li Wong, Richard Wilhelm Eek, Michael Michael, Jeanne Tie, Jennifer Rogers, Alexander Graham Heriot, David Ball, Michael Patrick MacManus, Rory Wolfe, Benjamin J Solomon

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

12116 Background: Interventional trials applying risk models for targeted-thromboprophylaxis (TP) for ambulatory cancer patients ..